Le Lézard
Classified in: Health
Subjects: POL, CPG, CFG, MAT

The governments of Canada and Nunavut collaborate to improve access to treatment for people with substance use disorders


OTTAWA, Dec. 10, 2018 /CNW/ - The opioid crisis continues to devastate individuals, families and communities across the country. Without increased access to effective, evidence-based treatment options, people with substance use disorder will continue to be at risk for overdose.

On Friday, the Honourable Ginette Petitpas Taylor, Minister of Health, and the Honourable George Hickes, Minister of Health for Nunavut, signed a bilateral agreement under the Government of Canada's Emergency Treatment Fund.

This agreement provides a total of $750,000?$500,000 in funding from the Government of Canada and $250,000 from the Government of Nunavut?to help increase access to treatment for people with substance use disorder.

This investment will fund the delivery of culturally appropriate and relevant treatment services to improve treatment opportunities for individuals with problematic substance use and trauma.  The result will be enhanced community-based systems that offer on-the-land healing camps and other community-based supports.

The Government of Canada and its partners recognize that helping people with problematic substance use access treatment?including in remote communities located in Canada's North?will ultimately help people who use drugs to live healthier lives.

Quotes

"Opioid-related overdoses continue to have a devastating impact in communities across Canada. I am pleased to be able to work with the Government of Nunavut to provide culturally appropriate treatment for substance use disorder and trauma. By improving access to treatment, this bilateral agreement will help communities to respond to the needs of people with problematic substance use. We must continue to work together in a comprehensive and collaborative way to help Canadians access treatment and supports."

The Honourable Ginette Petitpas Taylor
Minister of Health

"The Government of Nunavut is grateful for the opportunity to work collaboratively with the Government of Canada in the pursuit of increased access to substance use treatment opportunities for Nunavummiut. This partnership will help foster culturally appropriate approaches to improve treatment opportunities in Nunavut, and support the Department of Health in our commitment to education, outreach and prevention of problematic substance use in the territory."

The Honourable George Hickes
Minister of Health in Nunavut

Related Products

Backgrounder: Bilateral Agreement between the Government of Canada and the Government of Nunavut under the Emergency Treatment Fund
Emergency Treatment Fund

Associated Links

Infographic: Government of Canada ? Federal Actions on Opioids 
National report: Apparent opioid-related deaths in Canada 

 

SOURCE Health Canada


These press releases may also interest you

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...

3 jui 2024
In a landmark event signaling its ambitious foray into the biopharmaceutical sector, LOTTE BIOLOGICS, under the leadership of CEO Richard W. Lee, held a groundbreaking ceremony for its inaugural plant at the Songdo Bio Campus in Incheon International...

3 jui 2024
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for hematological malignancies, announced today that on July 2, 2024, in relation to...

3 jui 2024
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal...



News published on and distributed by: